Radioimmunotherapy: A Novel Treatment Modality for B-Cell Non-Hodgkin's Lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 673-674

  Juweid, Malik ^a,d   DeNardo, Gerald L ^b   Graham, Michael ^a,d   Vose, Julie ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; EDITORIAL; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 0242413854     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418229     Document Type: Editorial

References (5)

1. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled tiral of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
2. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
3. DeNardo GL, O'Donnell RT, Oldham RK, DeNardo SJ. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1998;13:213.
4. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice. J Nucl Med 2002;43:1507.
5. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of re lapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270.